ANNOUNCEMENT: Cambrex to invest $16.5 million in a new R&D facility in Minneapolis

- Cambrex will invest $16.

ANNOUNCEMENT: Cambrex to invest $16.5 million in a new R&D facility in Minneapolis

- Cambrex will invest $16.5 million in a new R&D facility in Minneapolis, Minnesota and an expansion in Charles City, Iowa

EAST RUTHERFORD, N.J., Oct. 27, 2022 /PRNewswire/ -- Cambrex announced today that it is investing in a new 21,000-square-foot research and development facility in Minneapolis, Minnesota, expanding its small molecule development and manufacturing capacity. Strategically located near the Minneapolis-St. Paul, the new facility will specialize in chemical and analytical development of drug candidates and will function as an extension of Cambrex's flagship facility in Charles City, Iowa. Cambrex is expected to add approximately 40 new jobs in the next 2- 3 years in the new headquarters in Minneapolis.

Cambrex will simultaneously launch a 9,000 square foot expansion and 21,000 square foot renovation project in Charles City, Iowa. The expansion will add a new quality control lab and administrative office space, creating 40 new management positions. I work at the plant. Extensive renovations will upgrade and modernize the current quality control and research and development facilities. The Iowa Economic Development Authority (IEDA) Board awarded the company tax benefits and $300,000 in direct financial aid to support expansion through the High Quality Jobs (HQJ) program.

"Our new facility in Minneapolis will double our chemical and analytical development footprint in the Midwest, providing customers with easy access to cutting-edge capabilities and top scientific experts," said Thomas Loewald, CEO of Cambrex. "We continue to invest in our US-based footprint to support the demand for high-quality API development and manufacturing."

This investment follows a previous $50 million expansion in Charles City that was completed in the first quarter of 2022, establishing Cambrex as the largest and most advanced active pharmaceutical ingredient (API) manufacturing site in the United States. The facility is located on a 45-acre property and produces a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.

About Cambrex

Cambrex is a world-leading contract development and manufacturing organization (CDMO) providing drug substance, pharmaceutical and testing services across the entire drug life cycle. With over 40 years of experience and a growing team of over 2,300 experts serving global customers in North America and Europe, Cambrex is a trusted partner in the brand and generic markets for the development and manufacturing of APIs and forms finished pharmaceuticals.

Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid state science, materials characterization, stability storage and highly potent APIs. In addition, Cambrex can support conventional dosage forms, including solids, semi-solids, and oral liquids, and has the expertise to manufacture specialized dosage forms such as modified release, fixed-dose combination, pediatric, bilayer tablets, stick packs, topicals, controlled, sterile and non-sterile ointments.

logo: link

View original content: enlace